Comparative study on clinical efficacy of a traditional Chinese patent medicines and simple preparations combined with levofloxacin in the treatment of type ? A chronic prostatitis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076329

Enrollment

Unknown

Registered

2023-10-03

Start date

2023-10-03

Completion date

Unknown

Last updated

2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic prostatitis

Interventions

Treatment group (levofloxacin+Huang'e capsules):levofloxacin+Huang'e capsules

Control group (levofloxacin):levofloxacin

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: ? Meets the diagnostic criteria for type IIIA chronic prostatitis; ? Age 18-60 years old; ? The course of the disease is more than 3 months; ? Those who did not receive relevant medication treatment within 2 weeks before enrollment; ? The patient and their family members are informed and sign an informed consent form.

Exclusion criteria

Exclusion criteria: ? Patients with acute abdominal pain, cystitis, acute prostatitis, urethritis, gonorrhea, acute and chronic enteritis, etc People with infectious diseases such as tuberculosis and viral hepatitis; ? Patients with benign prostatic hyperplasia, prostate cancer, urethral malformation or stenosis, neurogenic bladder, and other diseases; ? Patients with severe organ diseases, important organ dysfunction, tumors, and mental disorders; ? Individuals who are unable to tolerate the treatment regimen and medication used in this study.

Design outcomes

Primary

Measure	Time frame
NIHCPSI;EPS;	—

Countries

China

Contacts

Public Contactkinkai

Haining People's Hospital

406039137@qq.com+86 158 2430 6948

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026